A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
A new UK plan to use antigen tests for wide-scale screening for Covid-19 may not be the easy win the government is seeking.
The $13.1bn price suggests that Bristol could be banking on mavacamten’s potential outside rare diseases.